HomeARCT • NASDAQ
add
Arcturus Therapeutics Holdings Inc
$12.79
Makalipas ang Oras ng Trabaho:(0.47%)-0.060
$12.73
Sarado: Hun 6, 7:17:14 PM GMT-4 · USD · NASDAQ · Disclaimer
Nakaraang pagsara
$11.91
Sakop ng araw
$12.05 - $12.93
Sakop ng taon
$8.04 - $42.42
Market cap
346.87M USD
Average na Volume
445.45K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Sa balita
Mga Financial
Income Statement
Kita
Net na kita
| (USD) | Mar 2025info | Y/Y na pagbabago |
|---|---|---|
Kita | 29.38M | -22.70% |
Gastos sa pagpapatakbo | 11.32M | -23.81% |
Net na kita | -14.08M | 47.51% |
Net profit margin | -47.91 | 32.09% |
Kita sa bawat share | -0.52 | 48.00% |
EBITDA | -16.02M | 45.69% |
Aktuwal na % ng binabayarang buwis | — | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (USD) | Mar 2025info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 216.95M | -24.77% |
Kabuuang asset | 331.78M | -20.79% |
Kabuuang sagutin | 98.03M | -36.71% |
Kabuuang equity | 233.76M | — |
Natitirang share | 27.12M | — |
Presyo para makapag-book | 1.38 | — |
Return on assets | -12.45% | — |
Return on capital | -15.41% | — |
Cash Flow
Net change in cash
| (USD) | Mar 2025info | Y/Y na pagbabago |
|---|---|---|
Net na kita | -14.08M | 47.51% |
Cash mula sa mga operasyon | -35.14M | -532.32% |
Cash mula sa pag-invest | -137.00K | 42.92% |
Cash mula sa financing | 15.20M | 594.47% |
Net change in cash | -20.08M | -456.39% |
Malayang cash flow | -12.28M | -137.89% |
Tungkol
Arcturus Therapeutics Holdings Inc. is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA, messenger RNA, gene editing RNA, DNA, antisense oligonucleotides, and microRNA.
The company develops RNA therapeutics for the treatment of rare diseases such as ornithine transcarbamylase deficiency, and respiratory diseases such as cystic fibrosis. As of 2021, vaccine medicines include a vaccine candidate for COVID-19 and an influenza vaccine in the preclinical development phase. The vaccine for COVID-19 was authorised in Japan in 2023 and the European Union in 2025. Wikipedia
Itinatag
2013
Website
Mga Empleyado
175
